FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091323340> ?p ?o ?g. }

• W2091323340 endingPage "34" @default.
• W2091323340 startingPage "29" @default.
• W2091323340 abstract "This phase II study evaluated the response rate and tolerability of gemcitabine–oxaliplatin chemotherapy in non-small-cell lung cancer (NSCLC) patients. Chemonaive patients with stage IIIB or IV NSCLC received gemcitabine 1000 mg m−2 on days 1 and 8, followed by oxaliplatin 130 mg m−2 on day 1. Cycles were repeated every 21 days for up to six cycles. From February 2002 to May 2004, 60 patients were enrolled into the study in seven Italian institutions. We observed one complete response (1.7%) and 14 partial responses (23.3%), for an overall response rate of 25.0% (95% confidence interval, 14.7–37.9%). The median duration of response was 5.9 months (range 1.5–17.1 months). With a median follow-up of 6.7 months, median time to progressive disease and overall survival were 2.7 (range 1.9–3.4 months) and 7.3 months (range 7.2–8.6 months), respectively. The main grade 3–4 haematological toxicities were transient neutropenia in 11.7% and thrombocytopenia in 8.3% of the patients. Nausea/vomiting was the main grade 3–4 nonhaematological toxicity, occurring in 10.0% of the patients. Two (3.3%) patients developed grade 3 neurotoxicity. Our results show that gemcitabine–oxaliplatin chemotherapy is active and well tolerated in patients with advanced NSCLC, deserving further study, especially for patients not eligible to receive cisplatin." @default.
• W2091323340 created "2016-06-24" @default.
• W2091323340 creator A5001201465 @default.
• W2091323340 creator A5001428569 @default.
• W2091323340 creator A5001928949 @default.
• W2091323340 creator A5003664573 @default.
• W2091323340 creator A5008403882 @default.
• W2091323340 creator A5010570724 @default.
• W2091323340 creator A5021357646 @default.
• W2091323340 creator A5022006413 @default.
• W2091323340 creator A5034431443 @default.
• W2091323340 creator A5034509029 @default.
• W2091323340 creator A5059974723 @default.
• W2091323340 creator A5074954502 @default.
• W2091323340 creator A5078987153 @default.
• W2091323340 creator A5090055323 @default.
• W2091323340 date "2005-06-14" @default.
• W2091323340 modified "2023-10-16" @default.
• W2091323340 title "Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer" @default.
• W2091323340 cites W1837121308 @default.
• W2091323340 cites W1837926236 @default.
• W2091323340 cites W1848316250 @default.
• W2091323340 cites W1857358013 @default.
• W2091323340 cites W1858072261 @default.
• W2091323340 cites W1868450210 @default.
• W2091323340 cites W1935885922 @default.
• W2091323340 cites W1961110209 @default.
• W2091323340 cites W1983134727 @default.
• W2091323340 cites W1995002313 @default.
• W2091323340 cites W2001996041 @default.
• W2091323340 cites W2029409133 @default.
• W2091323340 cites W2032146688 @default.
• W2091323340 cites W2037139573 @default.
• W2091323340 cites W2050119069 @default.
• W2091323340 cites W2051667118 @default.
• W2091323340 cites W2059972525 @default.
• W2091323340 cites W2082598176 @default.
• W2091323340 cites W2095296145 @default.
• W2091323340 cites W2112089198 @default.
• W2091323340 cites W2122731269 @default.
• W2091323340 cites W2129793485 @default.
• W2091323340 cites W2130017050 @default.
• W2091323340 cites W2132865716 @default.
• W2091323340 cites W2137009016 @default.
• W2091323340 cites W2139248078 @default.
• W2091323340 cites W2142618187 @default.
• W2091323340 cites W2151322055 @default.
• W2091323340 cites W2160131381 @default.
• W2091323340 cites W2160354293 @default.
• W2091323340 cites W2166399931 @default.
• W2091323340 cites W2285157229 @default.
• W2091323340 cites W2285648066 @default.
• W2091323340 cites W4239714259 @default.
• W2091323340 cites W4293241248 @default.
• W2091323340 cites W4297939389 @default.
• W2091323340 cites W606431418 @default.
• W2091323340 doi "https://doi.org/10.1038/sj.bjc.6602667" @default.
• W2091323340 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361475" @default.
• W2091323340 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15956971" @default.
• W2091323340 hasPublicationYear "2005" @default.
• W2091323340 type Work @default.
• W2091323340 sameAs 2091323340 @default.
• W2091323340 citedByCount "28" @default.
• W2091323340 countsByYear W20913233402013 @default.
• W2091323340 countsByYear W20913233402014 @default.
• W2091323340 countsByYear W20913233402015 @default.
• W2091323340 countsByYear W20913233402016 @default.
• W2091323340 countsByYear W20913233402019 @default.
• W2091323340 crossrefType "journal-article" @default.
• W2091323340 hasAuthorship W2091323340A5001201465 @default.
• W2091323340 hasAuthorship W2091323340A5001428569 @default.
• W2091323340 hasAuthorship W2091323340A5001928949 @default.
• W2091323340 hasAuthorship W2091323340A5003664573 @default.
• W2091323340 hasAuthorship W2091323340A5008403882 @default.
• W2091323340 hasAuthorship W2091323340A5010570724 @default.
• W2091323340 hasAuthorship W2091323340A5021357646 @default.
• W2091323340 hasAuthorship W2091323340A5022006413 @default.
• W2091323340 hasAuthorship W2091323340A5034431443 @default.
• W2091323340 hasAuthorship W2091323340A5034509029 @default.
• W2091323340 hasAuthorship W2091323340A5059974723 @default.
• W2091323340 hasAuthorship W2091323340A5074954502 @default.
• W2091323340 hasAuthorship W2091323340A5078987153 @default.
• W2091323340 hasAuthorship W2091323340A5090055323 @default.
• W2091323340 hasBestOaLocation W20913233401 @default.
• W2091323340 hasConcept C121608353 @default.
• W2091323340 hasConcept C126322002 @default.
• W2091323340 hasConcept C141071460 @default.
• W2091323340 hasConcept C143998085 @default.
• W2091323340 hasConcept C197934379 @default.
• W2091323340 hasConcept C2776256026 @default.
• W2091323340 hasConcept C2776694085 @default.
• W2091323340 hasConcept C2777063308 @default.
• W2091323340 hasConcept C2778375690 @default.
• W2091323340 hasConcept C2780258809 @default.
• W2091323340 hasConcept C2780580376 @default.
• W2091323340 hasConcept C2780962732 @default.
• W2091323340 hasConcept C31760486 @default.
• W2091323340 hasConcept C526805850 @default.

• next